FDA.reportPublic FDA data

INSULIN ASPART

Substance profile for UNII D933668QVX, enriched with FDA NDC listings, DailyMed labels, legacy aliases, and open chemistry identifiers.

Chemical structure for INSULIN ASPART
Structure render from PubChem CID 118984445

Substance Identity#

UNII
D933668QVX
Preferred term
INSULIN ASPART
Registry number
116094-23-6
Ingredient type
INGREDIENT SUBSTANCE
Chemical structure for INSULIN ASPART
Structure render from PubChem CID 118984445

Chemical And Database Identifiers#

RxCUI
51428
PubChem
118984445
NCIt
C47563
INN ID
7541

Open Chemistry Sources#

Source, Identifier, Link table
SourceIdentifierLink
PubChem Compound118984445pubchem.ncbi.nlm.nih.gov/compound/118984445
RxNorm51428mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=51428
NCI ThesaurusC47563ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C47563
FDA Substance Registration SystemD933668QVXprecision.fda.gov/uniisearch/srs/unii/D933668QVX

DailyMed Socrata Ingredients#

Type, DailyMed label, SPL version table
TypeDailyMed labelSPL version
ACTIVE MOIETYThese highlights do not include all the information needed to use NovoLog safely and effectively. See full prescribing information for NovoLog. NovoLog (insulin aspart [rDNA origin] injection) solution for subcutaneous use Initial U.S. Approval: 2000 ®2
ACTIVE INGREDIENTThese highlights do not include all the information needed to use NovoLog safely and effectively. See full prescribing information for NovoLog. NovoLog (insulin aspart [rDNA origin] injection) solution for subcutaneous use Initial U.S. Approval: 2000 ®2
ACTIVE MOIETYThese highlights do not include all the information needed to use NovoLog safely and effectively. See full prescribing information for NovoLog. NovoLog ® (insulin aspart [rDNA origin] injection) solution for subcutaneous use Initial U.S. Approval: 20001
ACTIVE INGREDIENTThese highlights do not include all the information needed to use NovoLog safely and effectively. See full prescribing information for NovoLog. NovoLog ® (insulin aspart [rDNA origin] injection) solution for subcutaneous use Initial U.S. Approval: 20001
ACTIVE INGREDIENTThese highlights do not include all the information needed to use NovoLog Mix 70/30 safely and effectively. See full prescribing information for NovoLog Mix 70/30. NovoLog® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]) Suspension for subcutaneous injection Initial U.S. Approval: 20012
ACTIVE MOIETYThese highlights do not include all the information needed to use NovoLog Mix 70/30 safely and effectively. See full prescribing information for NovoLog Mix 70/30. NovoLog® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]) Suspension for subcutaneous injection Initial U.S. Approval: 20012
ACTIVE INGREDIENTNOVOLOG (INSULIN ASPART) INJECTION, SOLUTION [NOVO NORDISK]19
ACTIVE MOIETYNOVOLOG (INSULIN ASPART) INJECTION, SOLUTION [NOVO NORDISK]19
ACTIVE MOIETYNOVOLOG MIX 70/30 (INSULIN ASPART) INJECTION, SUSPENSION [NOVO NORDISK]16
ACTIVE INGREDIENTNOVOLOG MIX 70/30 (INSULIN ASPART) INJECTION, SUSPENSION [NOVO NORDISK]16